This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
by Ekta Bagri
ADMA stock slides after a short report sparks volatility, but management pushes back, citing strong Asceniv demand and steady fundamentals.
GRFSNegative Net Change ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
SMMT Stock Up 24% in Three Months: Here's What You Need to Know
by Zacks Equity Research
Summit Therapeutics stock jumps as FDA accepts ivonescimab BLA. Strong trial data and partnerships boost confidence in its cancer therapy pipeline.
GSKNegative Net Change MRKPositive Net Change SMMTPositive Net Change
biotechs
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
by Debanjana Dey
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
ADMANegative Net Change ALXONo Net Change BIAFNegative Net Change
biotechnology biotechs medical medical-devices
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
by Zacks Equity Research
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.
AGENPositive Net Change TGTXPositive Net Change INDVPositive Net Change
biotechs
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
by Zacks Equity Research
Intellia stock climbs nearly 20% in three months as pipeline progress, lifted FDA holds, and late-stage study updates boost investor optimism.
REGNPositive Net Change NTLANegative Net Change INDVPositive Net Change
biotechs
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q1 Results?
by Ahan Chakraborty
Eli Lilly's Q1 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
by Ekta Bagri
BMY's Breyanzi tops $1B run rate in 2025, expanding across five cancers with new FDA nod, strengthening its CAR T leadership despite rising competition.
NVSPositive Net Change BMYPositive Net Change GILDPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
by Ekta Bagri
ADMA stock plunges after a short report, but strong Asceniv demand, rising revenues, and margin expansion signal potential recovery ahead.
GRFSNegative Net Change ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Incyte Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to INCY stock based on the movements in the options market lately.
INCYPositive Net Change
biotechnology biotechs medical
TVTX Stock Soars on FDA Nod for Filspari in Second Kidney Indication
by Zacks Equity Research
Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.
INONegative Net Change ADMANegative Net Change TVTXPositive Net Change
biotechnology biotechs medical pharmaceuticals